| Identification | Back Directory | [Name]
Pomalidomide-PEG3-C2-NH2 (TFA) | [CAS]
2414913-97-4 | [Synonyms]
Thalidomide-NH-PEG3-NH2 TFA
Thalidomide-4-NH-PEG3-NH2 TFA
Pomalidomide-PEG3-C2-NH2 (TFA)
Cereblon Ligand-Linker Conjugates 5 (TFA)
E3 ligase Ligand-Linker Conjugates 30 (TFA) | [Molecular Formula]
C23H29F3N4O9 | [MDL Number]
MFCD32197253 | [MOL File]
2414913-97-4.mol | [Molecular Weight]
562.5 |
| Chemical Properties | Back Directory | [solubility ]
DMSO: 100 mg/mL (177.78 mM); Ethanol: 100 mg/mL (177.78 mM) | [form ]
Oil | [color ]
Light yellow to yellow | [Water Solubility ]
Water: 16.67 mg/mL (29.64 mM) |
| Hazard Information | Back Directory | [Uses]
Pomalidomide-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 5 (TFA)) is a synthetic E3 ligase ligand-linker conjugate comprising a Pomalidomide (HY-10984)-based cereblon ligand and a 3-unit PEG linker. Pomalidomide-PEG3-C2-NH2 TFA can be used for the synthesis of PROTACs[1]. | [Biological Activity]
Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. | [IC 50]
Cereblon | [References]
[1]. Li Y, et al. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. J Med Chem. 2019 Jan 24;62(2):448-466. |
|
|